|
Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of H1, an adjuvanted TB subunit vaccine in HIV-infected, BCG-vaccinated Adults With CD4+ Lymphocyte Counts Greater Than 350 Cells/mm3
Third-party funded project |
Project title |
Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of H1, an adjuvanted TB subunit vaccine in HIV-infected, BCG-vaccinated Adults With CD4+ Lymphocyte Counts Greater Than 350 Cells/mm3 |
Principal Investigator(s) |
Daubenberger, Claudia
|
Organisation / Research unit |
Swiss Tropical and Public Health Institute (Swiss TPH) / Molecular Immunology (Pluschke) |
Project start |
01.05.2011 |
Probable end |
01.05.2013 |
Status |
Completed |
Abstract |
Abstract will follow |
Financed by |
Swiss National Science Foundation (SNSF)
|
|
|
|
MCSS v5.8 PRO. 0.432 sec, queries - 0.000 sec
©Universität Basel | Impressum
| |
29/04/2024
Research Database / FORSCHUNGSDATENBANK
|